Could Nektar Therapeutics, Wave Life Sciences, and Savara go even higher after huge gains this past week?
Biogen stock is soaring while Gilead's is floundering. But which biotech is the better pick over the long run?
This biotech's future could be much brighter than its past.
Hint: Probably looking very good.
Which stock wins in a head-to-head battle between these pharmacy and retail giants?
Intuitive Surgical stock is red-hot. But could new competition cool things down in the near future?
AbbVie claims a No. 1 ranking among its big pharma peers in several key categories.
Aurora Cannabis' unsolicited bid to acquire CanniMed could shake up the marijuana industry in Canada -- and across the world.
Buy and hold for the next 13 years? It shouldn't be a problem with these stocks.
For Canopy Growth, short-term pain in its last quarter should result in long-term gain.
Looking for solid dividend stocks? Check out these big pharma winners.
Aurora Cannabis stock is soaring, for several reasons.
Healthcare won't be the same in the future because of these pioneers in gene editing, gene sequencing, and artificial intelligence.
Success appears to be in the company's DNA.
But there's at least one potentially huge market where the marijuana leader won't go.
Looking for great dividend stocks? Here are three of the best.
The recent sell-off has made Celgene stock a bargain. But that's not the only reason why it's smart to buy this biotech.
Which stock wins in a head-to-head matchup between a rising biotech star and an established big pharma leader?
Nektar, Sage, and Valeant stocks ranked among the biggest winners this week. But will their winning ways continue?
Sure, Dynavax has already chalked up huge gains. But there's still room for the biotech stock to go higher.